Restless legs syndrome: Understanding its consequences and the need for better treatment

Sleep Medicine

Volumn 11, Issue 9, 2010, Pages 807-815

  Earley, Christopher J ^a   Silber, Michael H ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mayo Clinic   (United States)

Author keywords

Augmentation; Cardiovascular disease; Dopamine agonists; Impulse control disorders; Insomnia; Quality of life; Restless legs syndrome

Indexed keywords

BENSERAZIDE; BENZODIAZEPINE DERIVATIVE; CABERGOLINE; CODEINE; DEXTROPROPOXYPHENE; DOPAMINE RECEPTOR STIMULATING AGENT; FERRIC HYDROXIDE SUCROSE; GABAPENTIN; GABAPENTIN ENACARBIL; IRON DEXTRAN; LEVODOPA; METHADONE; NARCOTIC AGENT; OPIATE; OXYCODONE; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE; TRAMADOL;

ANXIETY DISORDER; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FERRITIN BLOOD LEVEL; HUMAN; HYPERSEXUALITY; HYPERSOMNIA; IMPULSE CONTROL DISORDER; INSOMNIA; NAUSEA; NOSE DISEASE; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; UNSTEADINESS; VALVULAR HEART DISEASE;

ANXIETY DISORDERS; CARDIOVASCULAR DISEASES; DEPRESSIVE DISORDER; DOPAMINE AGENTS; HUMANS; IMPULSE CONTROL DISORDERS; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 79955053543     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2010.07.007     Document Type: Review

References (96)

1. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of health. Sleep Med 2003, 4:101-119.
2. Montplaisir J., Boucher S., Poirier G., Lavigne G., Lapierre O., Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997, 12:61-65.
3. Bucher S.F., Seelos K.C., Oertel W.H., Reiser M., Trenkwalder C. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol 1997, 41:639-645.
4. Earley C.J., Connor J.R., Beard J.L., Malecki E.A., Allen R.P. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000, 54:1698-1700.
5. Sun E.R., Chen C.A., Ho G., Earley C.J., Allen R.P. Iron and the restless legs syndrome. Sleep 1998, 21:371-377.
6. Caylak E. The genetics of sleep disorders in humans: narcolepsy, restless legs syndrome, and obstructive sleep apnea syndrome. Am J Med Genet A 2009, 149A:2612-2626.
7. Allen R.P., Walters A.S., Montplaisir J., et al. Restless legs syndrome prevalence and impact. REST general population study. Arch Intern Med 2005, 165:1286-1292.
8. Hogl B., Kiechl S., Willeit J., et al. Restless legs syndrome: a community-based study of prevalence, severity and risk factors. Neurology 2005, 64:1920-1924.
9. Tison F., Crochard A., KLeger D., Bouee S., Lainey E., El Hasnaoui A. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT study. Neurology 2005, 65:239-246.
10. Lavigne G.J., Montplaisir J.Y. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994, 17:739-743.
11. Nichols D.A., Allen R.P., Grauke J.H., et al. Restless legs syndrome symptoms in primary care. A prevalence study. Arch Intern Med 2003, 163:2323-2329.
12. Phillips B., Hening W., Britz P., Mannino D. Prevalence and correlates of restless legs syndrome. Results from the 2005 National Sleep Foundation poll. Chest 2006, 129:76-80.
13. Allen R.P., Stillman P., Myers A.J. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in Western Europe: prevalence and characteristics. Sleep Med 2010, 11:31-37.
14. Abetz L., Allen R., Follet A., et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004, 26:925-935.
15. Berger K., Luedemann J., Trenkwalder C., John U., Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004, 164:196-202.
16. Kushida C., Martin M., Nikam P., et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007, 16:617-624.
17. Allen R.P., Walters A.S., Montplaisir J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165:1286-1292.
18. West E., Wållberg-Jonsson S. Health-related quality of life in Swedish men and women with early rheumatoid arthritis. Gender Med 2009, 6:544-554.
19. Rudolph T., Larsen J.P., Farbu E. Is there a need for long-term follow-up in chronic idiopathic polyneuropathy?. Acta Neurol Scand 2009, 120:347-352.
20. Picchietti D.L., Winkelman J.W. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005, 28:891-898.
21. Hornyak M. Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management. CNS Drugs 2010, 24:89-98.
22. Rothdach A.J., Trenkwalder C., Haberstock J., Keil U., Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology 2000, 54:1064-1068.
23. Sukegawa T., Itoga M., Seno H., et al. Sleep disturbances and depression in the elderly in Japan. Psychiatry Clin Neurosci 2003, 57:265-270.
24. Winkelmann J., Prager M., Lieb R., et al. "Anxietas tibiarum" Depression and anxiety disorders in patients with restless legs syndrome. J Neurol 2005, 252:67-71.
25. Ulfberg J., Nystrom B., Carter N., Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001, 16:1159-1163.
26. Ohayon M.M., Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002, 53:547-554.
27. Winkelman J.W., Finn L., Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006, 7:545-552.
28. Winkelman J.W., Shahar E., Sharief I., Gottlieb D.J. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008, 70:35-42.
29. Pennestri M.H., Montplaisir J., Colombo R., Lavigne G., Lanfranchi P.A. Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology 2007, 68:1213-1218.
30. Walters A.S., Rye D.B. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 2009, 32:589-597.
31. Oertel W.H., Stiasny-Kolster K., Bergtholdt B., et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007, 22:213-219.
32. Trenkwalder C., Garcia-Borreguero D., Montagna P., et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004, 75:92-97.
33. Walters A.S., Ondo W., Dreykluft T., Grunstein R., Lee D., Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double blind, randomized parallel-group, placebo-controlled study. Mov Disord 2004, 19:1414-1423.
34. Winkelman J.W., Sethi K.D., Kushida C.A., et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006, 67:1034-1039.
35. Ondo W., Romanyshyn J., Vuong K.D., Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004, 61:1393-1397.
36. Silber M., Girish M., Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003, 26:819-821.
37. Montplaisir J., Fantini M.L., Desautels A., Michaud M., Petit D., Filipini D. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006, 13:1306-1311.
38. Allen R., Becker P.M., Bogan R., et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004, 27:907-914.
39. Stiasny K., Moller J.C., Oertel W.H. Safety of pramipexole in patients with restless legs syndrome. Neurology 2000, 55:1589-1590.
40. Garcia-Borreguero D., Allen R.P., Kohnen R., et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007, 8:520-530.
41. Garcia-Borreguero D, Williams A. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 2010. doi:10.1016/j.smrv.2009.11.006. doi:10.1016/j.smrv.2009.11.006.
42. Allen R.P., Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996, 19:205-213.
43. Hogl B., Garcia-Borreguero D., Kohnen R., et al. Progressive development of augmentation during long term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010, 257:230-237.
44. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 2002, 3:S23-S25.
45. Winkelman J.W., Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004, 5:9-14.
46. Frauscher B., Gschliesser V., Brandauer E., et al. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med 2009, 10:611-615.
47. Trenkwalder C., Hogl B., Benes H., Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2008, 9:572-574.
48. Winkelman J.W., Bennett S. Augmentation with pramipexole in the long-term treatment of restless legs syndrome. Sleep 2002, 25:A253.
49. Voon V., Hassan K., Zurowski M., et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006, 67:1254-1257.
50. Bostwick J.M., Hecksel K.A., Stevens S.R., Bower J.H., Ahlskog J.E. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc 2009, 84:310-316.
51. Evans A.H., Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord 2007, 22:590-599.
52. Quickfall J., Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 2007, 13:535-536.
53. Salas R.E., Allen R.P., Earley C.J., Gamaldo C.E. A case of compulsive behaviors observed in a restless legs syndrome patient treated with a dopamine agonist. Sleep 2009, 32:587-588.
54. Driver-Dunkley E.D., Noble B.N., Hentz J.G., et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007, 30:249-254.
55. Ondo W.G., Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008, 14:28-32.
56. Cornelius J.R., Tippmann-Peikert M., Slocumb N.L., Frerichs C.F., Silber M.H. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010, 33:81-87.
57. Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis 2010. doi:10.1016/j.nbd.2010.03.013. doi:10.1016/j.nbd.2010.03.013.
58. Stiasny-Kolster K., Kohnen R., Schollmayer E., Moller J.C., Oertel W.H., Group R.S.S. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004, 19:1432-1438.
59. Cilia R., Siri C., Marotta G., et al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 2008, 65:1604-1611.
60. Abler B., Hahlbrock R., Unrath A., Gron G., Kassubek J. At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists. Brain 2009, 132:2396-2402.
61. Steeves T.D., Miyasaki J., Zurowski M., et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009, 132:1376-1385.
62. Hening W., Allen R., Earley C., et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine review. Sleep 2004, 27:560-583.
63. Junghanns S., Fuhrmann J.T., Simonis G., et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 2006, 22:234-238.
64. Schade R., Andersohn F., Suissa S., Haverkamp W., Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Eng J Med 2007, 356:29-38.
65. Yamamoto M., Uesugi T., Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease. A case-control study. Neurology 2006, 67:1225-1229.
66. Trenkwalder C., Benes H., Poewe W., et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008, 7:595-604.
67. Benes H., Garcia-Borreguero D., Allen R., Kohnen R. Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine - a retrospective systematic analysis of two large open-label 1-year trials. Sleep 2009, 32:A307.
68. Kaplan P.W., Allen R.P., Buchholz D.W., Walters J.K. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993, 16:717-723.
69. Walters A.S., Wagner M., Hening W., et al. Succesful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993, 16:327-332.
70. Walters A.S., Winkelmann J., Trenkwalder C., et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Dis 2001, 16:1105-1109.
71. Webster L.R., Choi Y., Desai H., Webster L., Grant B.J. Sleep-disordered breathing and chronic opioid therapy. Pain Med 2008, 9:425-432.
72. Earley C.J., Allen R.P. Restless legs syndrome augmentation associated with tramadol. Sleep Med 2006, 7:592-593.
73. Garcia-Borreguero D., Larrosa E., DelaLlave Y., Verger K., Masramon X., Hernandez G. Treatment of restless legs syndrome with gabapentin. A double-blind, cross-over study. Neurology 2002, 59:1573-1579.
74. Thorp M.L., Morris C.D., Bagby S.P. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001, 38:104-108.
75. Garcia-Borreguero D., Larrosa O., Alvares J., Pascual M., Fernandez C., Palacios C. Effective treatment of idiopathic restless legs syndrome with pregabalin: a twelve-week, double-blind, placebo-controlled study with clinical and polysomnographic assessment. Sleep 2009, 32:A294.
76. Walters A.S., Ondo W.G., Kushida C.A., et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009, 32:311-320.
77. Boghen D., Lamothe L., Elie R., Godbout R., Montplaisir J. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci 1986, 13:245-247.
78. Montagna P., Sassoli de Bianchi L., Zucconi M., Cirignotta F., Lugaresi E. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 1984, 69:428-430.
79. Hoque R., Chesson A.L.J. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 2009, 5:471-476.
80. Davis B.J., Rajput A., Rajput M.L., Aul E.A., Eichhorn G.R. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000, 43:70-75.
81. Wang J., O'Reilly B., Venkataraman R., Mysliwiec V., Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med 2009, 10:945-946.
82. Earley C.J., Horska A., Mohamed M.A., Barker P.B., Beard J.L., Allen R.P. A randomized, double-blind, placebo-controlled trail of intravenous iron sucrose in restless legs syndrome. Sleep Med 2009, 10:206-211.
83. Grote L., Leissner L., Hedner J., Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009, 24:1445-1452.
84. Bassetti C.L., Mauerhofer D., Gugger M., Mathis J., Hess C.W. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol 2001, 45:67-74.
85. Hening W., Walters A.S., Allen R.P., Montplaisir J., Myers A., Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004, 5:237-246.
86. Bjorvatn B., Leissner L., Ulfberg J., et al. Prevalence, severity and risk factors of restless legs symdrome in the general adult population in two Scandinavian countries. Sleep Med 2005, 6:307-312.
87. Ulfberg J., Bjorvatn B., Leissner L., et al. Comorbidity in restless legs syndrome among a sample of Swedish adults. Sleep Med 2007, 8:768-772.
88. Broman J., Mallon L., Hetta J. Restless legs syndrome and its relationship with insomnia symptoms and daytime distress: epidemiological survey in Sweden. Psychiatry Clin Neurosci 2008, 62:472-475.
89. Saletu B., Anderer P., Saletu M., Hauer C., Lindeck-Pozza L., Saletu-Zyhlarz G. EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med 2002, 3:S35-S42.
90. Hornyak M., Feige B., Voderholzer U., Philipsen A., Riemann D. Polysomnography findings in patients with restless legs syndrome and in healthy controls: a comparative observational study. Sleep 2007, 30:861-865.
91. Winkelman J.W., Redline S., Baldwin C.M., Resnick H.E., Newman A.B., Gotllieb D.J. Polysomnographic and health-related quality of life correlates of restless legs syndrome in the sleep heart health study. Sleep 2009, 32:772-778.
92. Mosko S., Zetin M., Glen S., et al. Self-reported depressive symptomatology, mood ratings, and treatment outcome in sleep disorders patients. J Clin Psychol 1989, 45:51-60.
93. Banno K., Delaive K., Walld R., Kryger M.H. Restless legs syndrome in 218 patients: associated disorders. Sleep Med 2000, 1:221-230.
94. Vandeputte M., de Weerd A. Sleep disorders and depressive feelings: a global survey with the Beck depression scale. Sleep Med 2003, 4:343-345.
95. Sevim S., Dogu O., Kaleagasi H., Aral M., Metin O., Camdeviren H. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry 2004, 75:226-230.
96. Lee H.B., Hening W.A., Allen R.P., et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 2008, 20:101-105.